Dashboard · Pharmaceuticals stocks · AUROPHARMA
32
JayScore

Aurobindo Pharma Limited

AUROPHARMA Pharmaceuticals
Weak Setup Grade C 35% confidence
Score computed at ₹1,627.50 · 27 Oct 2026
Research signals 0 positive · 8 cautionary of 8
NSE
JayScore
32
vs
Sector signal
2
32
Aurobindo Pharma Limited AUROPHARMA Weak Setup
Get notified when this stock's JayScore changes
Free account — score alerts, daily research picks, morning plan and portfolio tracker.
Sign Up Free Sign In
About Aurobindo Pharma Limited

Aurobindo Pharma Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹90,432 crore. The company reports a net profit margin of 10.6%. Revenue grew +16.3% year-over-year. Promoter holding stands at 54.8%, with FII participation at 29.4%.

Pharmaceuticals sector signal: 2/100 — below-average — fewer than 40% of sector peers are trading above their EMA 20.
JayScore 32/100 indicates a cautionary signal — research factors show weakness across one or more key dimensions. JayScore is a quantitative index — not investment advice. Learn how it's calculated →
JaySense Research View · quantitative signals only · not investment advice
Weak Setup

Most stocks in the same industry are struggling (sector — most peers below EMA20). The uptrend is visible even on the weekly chart (longer-term trend confirmed). The overall market is in a downtrend — all trades carry higher risk right now (BEAR MARKET regime, reduced confidence). Approaching its key breakout zone — watch for a volume-backed close above resistance to confirm entry.

Watch Points
Momentum is fading or showing negative divergence
Fundamental score is weak relative to benchmark
Sector is under pressure — headwinds may persist
Institutional activity is low or declining
Only 2 of 9 research signals are aligned
📅 Earnings on 05 Nov (9 days). Results can move price sharply — up or down.
Research Score Insight

Aurobindo Pharma Limited scores 32/100 (Weak Research Signal). The strongest signals are Trend (8/100) and Risk Profile (6/100). The weakest dimension is Fundamental Quality (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.

Trend 8 Momentum 5 Volume 5 Fundamental 0 Valuation 3 Growth 5 Institutional 1 Sector 2 Risk 6
Research Intelligence Free Account Required
0 positive · 9 risk signals identified 2 / 9 signals converging
Downtrend active — price has broken below key moving averages
Institutional indicators suggest active accumulation in this price zone
Volatility ratio and momentum signal caution at current levels
Institutional indicators suggest active accumulation in this price zone
Volatility ratio and momentum signal caution at current levels

8 more research signals — available free with a JaySense account

Get Free Access Sign in
Sector & Institutional Activity Free Account Required
Sector Health
2.4000/100
Sector Rank
#3 of 12
FII Activity
Net Buying
FII net buyers ₹840 Cr over last 10 sessions — institutional accumulation in progress
DII activity supportive — domestic funds adding to position

Sector peer rank, FII/DII trend & institutional activity — free with a JaySense account

Get Free Access Sign in
Score Analysis
Trend
8
Weak
Price vs moving averages · trend structure
Momentum
5
Weak
MACD · RSI · rate-of-change
Volume
5
Weak
Volume strength · accumulation vs distribution
Fundamental
0
Weak
Margins · returns · debt ratios
Valuation
3
Weak
PE · PB · multiples vs sector
Growth
5
Weak
Revenue & profit growth YoY
Sector
2
Weak
Sector relative strength vs market
Risk
6
Weak
Volatility · beta · drawdown risk
Institutional
1
Weak
FII / DII participation & block deals
Signal convergence: 2 / 9 dimensions aligned · Low convergence
Score Trend (Last 30 Scores)
Fundamentals
Market Cap
₹90,432 Cr
P/E Ratio
24.56
P/B Ratio
2.41
EPS (TTM)
64
ROE
—
ROCE
—
Net Profit Margin
10.6%
Debt / Equity
21.31
Revenue Growth YoY
16.3%
Profit Growth YoY
25.8%
Promoter Holding
54.8%
FII Holding
29.4%
Dividend Yield
0%
Company Profile
Aurobindo Pharma Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹90,432 crore. The company reports a net profit margin of 10.6%. Revenue grew +16.3% year-over-year. Promoter holding stands at 54.8%, with FII participation at 29.4%.
How JaySense scores stocks Full stock screener
Disclaimer: JaySense scores are research outputs based on technical and fundamental signals. They are not buy/sell recommendations and do not constitute investment advice. Past score performance does not guarantee future returns. Please do your own research or consult a SEBI-registered investment advisor before making any investment decision. JaySense is not SEBI-registered. Use this platform for educational and research purposes only.